Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Balaxi Pharmaceuticals Limited ( (IN:BALAXI) ) has issued an announcement.
Balaxi Pharmaceuticals Limited has disclosed that its registrar and share transfer agent, Aarthi Consultants Private Limited, has submitted the prescribed report on re-lodgement of transfer requests for physical shares for the period ended April 2026, in line with a recent SEBI circular. The company reported that no shareholder requests for re-lodgement of physical share transfers were received, processed, approved, or rejected during the month, indicating minimal investor activity in this legacy share transfer channel, and has made the report available on its website for investors’ reference.
The filing underscores Balaxi Pharmaceuticals’ compliance with updated SEBI norms governing physical share transfers and the special window for re-lodgement, even as most trading has shifted to dematerialised form. For stakeholders, the nil figures suggest that the company’s shareholder base is largely aligned with the broader market transition away from physical securities, reducing operational and administrative risks associated with paper-based share transfers.
More about Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited is an India-based pharmaceutical company engaged in manufacturing and marketing generic medicines. The company focuses on supplying branded generics and formulations to emerging markets and serves a broad base of retail and institutional healthcare customers.
Average Trading Volume: 141,062
Technical Sentiment Signal: Sell
Current Market Cap: 1.61B INR
For a thorough assessment of BALAXI stock, go to TipRanks’ Stock Analysis page.